BIOV — BioVersys AG Income Statement
0.000.00%
Last trade - 00:00- CH₣151.41m
- CH₣168.37m
Annual income statement for BioVersys AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 17.7 | 18.7 |
| Operating Profit | -17.7 | -18.7 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -18.3 | -18.7 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -18.3 | -18.7 |
| Net Income Before Extraordinary Items | ||
| Net Income | -18.3 | -18.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -18.3 | -18.7 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -56.5 | -57 |